TGF-beta1 drives partial myofibroblastic differentiation in chondromyxoid fibroma of bone.
Authors
Romeo, SalvatoreEyden, Brian P
Prins, Frans A
Briaire-de Bruijn, Inge H
Taminiau, Antonie H M
Hogendoorn, Pancras C W
Affiliation
Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands.Issue Date
2006-01
Metadata
Show full item recordAbstract
Chondromyxoid fibroma (CMF) is a rare benign cartilaginous bone tumour with a lobular architecture containing stellate and myofibroblast-like spindle cells. The aim of this study was to investigate the presence, spatial distribution, and extent of myoid differentiation in CMF and to evaluate a possible causative role for TGF-beta1 signalling, which is known to promote smooth muscle actin (SMA) expression. Twenty cases were studied for immunoreactivity for muscle-specific actin (MSA), SMA, desmin, h-caldesmon, calponin, TGF-beta1, and plasminogen activator inhibitor type 1 (PAI-1). The extent of myofibroblastic differentiation was further investigated ultrastructurally, including immuno-electron microscopy using antibodies against MSA and SMA, focusing upon the different cell types in CMF. The expression of potential genes driving this process was quantified by Q-RT-PCR (TGF-beta1, fibronectin, its EDA splice variant, and PAI-1). Tumour cells, especially those with a spindled morphology, showed diffuse immunoreactivity for MSA, SMA, TGF-beta1, and PAI-1, while desmin, h-caldesmon, and calponin were absent. Ultrastructurally, neoplastic cells showed the presence of myofilaments and rare dense bodies, which were more prominent in spindle cells and less so in chondroblast-like cells. Immuno-electron microscopy confirmed the actin nature of these myofilaments. No fibronexus was identified. The functional activity of TGF-beta1 was demonstrated by the identification of PAI-1, a related downstream molecule both immunohistochemically as well as by Q-RT-PCR. There was a linear correlation between TGF-beta1 and PAI-1 expression. Fibronectin-EDA levels were low. We have therefore substantiated the presence of morphological, immunohistochemical, and immuno-electron microscopic partial myofibroblastic differentiation in CMF, driven by TGF-beta1 signalling.Citation
TGF-beta1 drives partial myofibroblastic differentiation in chondromyxoid fibroma of bone. 2006, 208 (1):26-34 J. Pathol.Journal
The Journal of PathologyDOI
10.1002/path.1887PubMed ID
16278817Type
ArticleLanguage
enISSN
0022-3417ae974a485f413a2113503eed53cd6c53
10.1002/path.1887
Scopus Count
Collections
Related articles
- Chondromyxoid fibroma: a tumor showing myofibroblastic, myochondroblastic, and chondrocytic differentiation.
- Authors: Nielsen GP, Keel SB, Dickersin GR, Selig MK, Bhan AK, Rosenberg AE
- Issue date: 1999 May
- Differential expression of smooth muscle myosin, smooth muscle actin, h-caldesmon, and calponin in the diagnosis of myofibroblastic and smooth muscle lesions of skin and soft tissue.
- Authors: Perez-Montiel MD, Plaza JA, Dominguez-Malagon H, Suster S
- Issue date: 2006 Apr
- Induction of the myofibroblastic phenotype in human gingival fibroblasts by transforming growth factor-beta1: role of RhoA-ROCK and c-Jun N-terminal kinase signaling pathways.
- Authors: Smith PC, Cáceres M, Martinez J
- Issue date: 2006 Oct
- Sphingosylphosphorylcholine induces differentiation of human mesenchymal stem cells into smooth-muscle-like cells through a TGF-beta-dependent mechanism.
- Authors: Jeon ES, Moon HJ, Lee MJ, Song HY, Kim YM, Bae YC, Jung JS, Kim JH
- Issue date: 2006 Dec 1
- Inflammatory myofibroblastic tumor and low-grade myofibroblastic sarcoma: a comparative study of clinicopathologic features and further observations on the immunohistochemical profile of myofibroblasts.
- Authors: Qiu X, Montgomery E, Sun B
- Issue date: 2008 Jun